290
Participants
Start Date
November 14, 2023
Primary Completion Date
January 9, 2029
Study Completion Date
January 9, 2030
PF-08046052
Given into the vein (IV; intravenously)
RECRUITING
Atrium Health Wake forest Baptist, Winston-Salem
RECRUITING
Atrium Health Wake forest Baptist, Winston-Salem
RECRUITING
Wake Forest Baptist Medical Center / Wake Forest University, Winston-Salem
RECRUITING
Moffitt Cancer Center McKinley Hospital, Tampa
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
University Hospitals Cleveland Medical Center, Cleveland
RECRUITING
Karmanos Cancer Institute, Detroit
RECRUITING
Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills
RECRUITING
University of Iowa, Iowa City
RECRUITING
MD Anderson Cancer Center - University of Texas, Houston
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Huntsman Cancer Hospital, University of Utah, Salt Lake City
RECRUITING
Huntsman Cancer Institute, University Of Utah, Salt Lake City
RECRUITING
Ronald Reagan UCLA Medical Center, Los Angeles
RECRUITING
UCLA Hematology/Oncology, Los Angeles
RECRUITING
Santa Monica UCLA Medical Center & Orthopaedic Hospital, Santa Monica
RECRUITING
UCLA Hematology/Oncology - Santa Monica, Santa Monica
RECRUITING
Providence Cancer Institute Franz Clinic, Portland
RECRUITING
Providence Portland Medical Center, Portland
RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
Hackensack University Medical Center, Hackensack
RECRUITING
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RECRUITING
University College London Hospital, NIHR UCLH Clinical Research Facility, London
RECRUITING
The Christie NHS Foundation Trust, Manchester
Seagen, a wholly owned subsidiary of Pfizer
INDUSTRY